To account for the superior prognosis of hyperdiploid, B-progenitor acute lymphoblastic leukemia (ALL), we investigated the influence of trisomy in 1021 children 2 1 year old by recursive partitioning analysis. The patients were treated according to a stratified, randomized study testing antimetabolite-based therapies. Trisomies of several individual chromosomes were associated with a better prognosis in a univariate statistical analysis. Of greater importance, trisomy of both chromosomes4 and 10 identified a subgroup of patients (n = 180) with an extremely favorable 4-year event-free survival (EFS). Combined trisomy of chromosomes 4 and 10 retained its prognostic significance after stratification of patients by DNA index, age, and leukocyte count. Among patients with a DNA index greater than 1.16, patients with trisomies of both chromosomes 4 and 10 had a 4-year EFS of HE RECENT MARKED improvement in cure rates T for children with acute lymphoblastic leukemia (ALL) has focused attention on better methods of identifying patients with increased or decreased risk of treatment failure. The aim of such analyses is to further the development of risk-directed therapy-an especially important goal in children, whose rapid growth makes them highly susceptible to treatment-related morbidity. Unfortunately, most prognostic factors depend on treatment so that no single factor or combination of factors consistently identifies patients who can be assigned to minimal treatment with confidence in a successful outcome.
T for children with acute lymphoblastic leukemia (ALL) has focused attention on better methods of identifying patients with increased or decreased risk of treatment failure. The aim of such analyses is to further the development of risk-directed therapy-an especially important goal in children, whose rapid growth makes them highly susceptible to treatment-related morbidity. Unfortunately, most prognostic factors depend on treatment so that no single factor or combination of factors consistently identifies patients who can be assigned to minimal treatment with confidence in a successful outcome.
Over the past decades, certain genetic features of leukemic cells, including chromosome number (ploidy) and nonrandom recurring chromosomal translocations, were identified as independent predictors of treatment outcome in childhood ALL.'-" Hyperdiploid ALL ( > 50 chromosomes) has been shown to confer a favorable prognosis, while translocations such as the t(9;22) and t(1;19) have been related to a suboptimal ~u t c o m e .~,~,~~,~~ When considered together with clinical risk factors, hyperdiploidy was associated with 4 year event-free survival (EFS) of 75% to 80% among children with B-progenitor
In an effort to refine our observations on the prognostic importance of trisomy of leukemic cell chromosomes9 in the context of effective antimetabolite-based therapy, we examined the leukemia cell karyotypes of a large group of children with B-progenitor cell ALL and correlated the results with treatment outcome. We examine here, by recursive partitioning methods, which specific trisomies contribute independent prognostic significance, thereby identifying a subgroup of patients who are likely to benefit from such therapy.
Recursive partitioning and amalgamation analysis attempts to determine which variables in a set of binary (yes/no) indicators have independent prognostic importance. The method uses the following steps. In the first partition attempt, the patient sample is analyzed according to a prospectively defined criterion to determine the singly most significant prognostic factor, assuming that at least one significant factor can be found. This will subdivide the patient sample into two subgroups, those with versus those without this factor. In the second partition attempt, each of these two subgroups is then individually analyzed in exactly the same way to attempt to subdivide each group. This second step could lead to the creation of two groups (if no variable is prognostically significant in either subgroup); three groups (if one of the subgroups has prognostically significant variables while the other does not); or four groups (if both subgroups have prognostically significant variables). In the first amalgamation attempt, we compare each pair of adjacent groups, if more than two groups are defined, starting with the group at the highest risk, and attempt to combine groups if there is no Significant differ-ence in outcome. Newly defined groups are subjected to partition attempts followed by amalgamation attempts until no further partition or amalgamation meet the significance criterion set forth in the algorithm. The total patient population is subdivided into two distinct groups before conducting the analysis. The first group (50% of the patients) is used to build the test model as given above. The second or verification dataset is used for inferences about the model. It is the verification process that keeps the studywise error rate under control, because very few statistical tests are conducted on the verification dataset. Additional technical information on this approach appears in the Statistical Considerations. (Table 1) and form the basis for the analyses that follow. The cutoff for analysis was May 2,1991.
MATERIALS AND METHODS

Patients
Details of the four treatment regimens, including drug schedules and doses, have been published previously and are summarized in Fig l.15,16 Briefly, induction therapy (see legend to Fig 1) comprised vincristine, prednisone, and asparaginase with triple intrathecal chemotherapy (methotrexate, hydrocortisone, cytarabine), followed by intensification with: regimen A, moderate-dose methotrexate (MTX); regimeh B, moderate-dose MTX plus asparaginase; regimen C, moderate-dose MTX plus cytarabine administered over 16 weeks; and regimen D, moderate-dose MTX plus cytarabine administered over 14 months. Continuation therapy comprised daily mercaptopurine and weekly methotrexate until 3 years from diagnosis; vincristine and prednisone pulses as systemic intensification, and triple intrathecal therapy to prevent relapse in the central nervous system (CNS) were administered for 2 years.
Risk-group assignment was primarily based on age, leukocyte count ( Table 2 and Pullen et all4), as well as on immunophenotype (ie, early pre-B v pre-B), because of the expected inferior prognosis of pre-B versus early pre-B patients.'* Patients at lower risk of relapse with early pre-B ALL were randomized to receive one of the four regimens, whereas higher-risk patients received only Immunologic cell fyping. Bone marrow cells were separated on a Ficoll-Hypaque gradient. Cell surface antigens were detected by a standard indirect immunofluorescence assay with monoclonal antibodies to lymphoid-associated antigens. Cells were analyzed for fluorescent activity by flow cytometry (FACScan; Becton Dickison, San Jose, CA). Blast cells were also tested for surface Ig (slg) and cytoplasmic Ig (clg) using a visual immunofluorescence assay. Depending on the pattern of reactivity, cells were classified as T (positive for at least two of the following antigens: CD7, CD5, and CD2), B(sIg+), pre-B(cIg+), or early pre-B (CD19+, CD22=, CD24*, CDlO', cIg-, sIg-, CD7-, CD5-, and CD2-). Patients were classified as having pre-B cell ALL if 2 10% of their bone marrow blast cells contained cIg. Only patients with pre-B or early pre-B ALL and age greater than 1 year at diagnosis were enrolled in the ALinC- 14.19s20 Bone marrow samples were processed by standard cytogenetic methods. Cases were classified on the basis of numerical chromosomal abnormalities (gain or loss of whole chromosomes) or structural abnormalities (translocations, deletions, duplications, isochromosomes, inversions, and unclassifiable markers), according to the International System for Human Cytogenetic Nomenclature.21 Cellular DNA content determinations were made by flow cytometry to derive the DNA index (ratio of DNA content in leukemic Go/GI cells to that in normal diploid cells)," which was then used to distinguish to prognostic categories of leukemic cells: those with DNA indexes 11. 16 or > 1. 16 (approximately equal to <53 or 253 chromosomes).
Complete remission was defined as less than 5 mononuclear cells/pL of cerebrospinal fluid and 1 5% lymphoblasts in marrow aspirates; evidence of regeneration of normal marrow cells; absence of symptoms and signs attributable to leukemia; and a clinical performance status that had largely returned to full function. EFS was defined as the interval between attainment of a complete response and the earliest of the following events: relapse, death from any cause, or date of last contact. Patients who failed to enter remission were considered failures at time zero.
CNS leukemia was diagnosed on the basis of cranial nerve palsies, with or without leukemic blasts in the cerebrospinal fluid, or when mononuclear cell counts of 2 5 cells/kL and leukemic blasts were present in Wright-stained cytocentrifuged samples of spinal fluid. The diagnosis of testicular leukemia required confirmation by open biopsy.
Statistical considerations. The hazard ratio is the ratio of instantaneous risk of treatment failure for patients with that specific trisomy to the instantaneous risk of failure in the absence of that trisomy. EFS was the dependent variable in all analyses. Twenty-four independent variables were defined according to Cytochemical studies.
Cytogenetic analysklDNA frow cytomehy.
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Recursive partitioning and amalgamation analysis, using a modification of Ciampi et al,' similar to that of Trueworthy et al,I3 and to that of Shuster et al,24 was used. The data were divided into two subsets: those with even POG identification numbers served as the test (modeling) set, whereas those with odd POG identification numbers served as the verification data set. Because recursive partitioning and amalgamation entails a large number of statistical tests, the verification process is vital as protection against spurious findings.
In recursive partitioning and amalgamation analysis, a subgroup is partitioned if an independent variable has a P value of less than 1%, based on univariate Cox regression analysis. 25 The variable chosen for the partition is the one with the smallest estimated hazard ratio among those meeting the P < .01 criterion. Amalgamation is attempted after each partitioning procedure by comparing adjacent risk groups (starting with the highest) by univariate Cox regression analysis, and combining them if P is > .05. The procedure is restricted to the test data set, starting with all patients in the subset, and continuing until no further partitions or amalgamations can be completed. The P values for each partition and amalgamation, together with comparison of the final resulting stages, are provided for the test and verification data sets. It is within the verification subset that inferences about the model should be made. This method of analysis has advantages and disadvantages compared with the more traditional stepwise Cox regression. Most important is the ability to detect subset specific factors. The stepwise Cox model assumes that the log of the true hazard ratio is linear in the covariates. This means that the hazard ratio for one trisomy is assumed to be the same, irrespective of the value of other covariates previously entered in the model. The stepwise Cox model may therefore find a significant factor in a very good risk group, only as an artifact of its significance in a poor-risk group. While the hazard ratio estimates of both methods require proportional hazards assumptions to be valid, the P values of recursive partition are valid at every step of the recursive partition and amalgamation process as a test of the null hypothesis of no prognostic importance. Only the first step of the stepwise Cox
procedure has this property. The recursive partitioning method uses smaller and smaller modelling data sets as the process continues, whereas the stepwise Cox procedure uses the entire data set to establish each significant variable. This is an advantage to the stepwise Cox model, if indeed a linear model in the log hazard ratios is valid. In such a situation, the stepwise Cox model will have a higher power of detecting truly prognostic trisomies.
Our combined use of the hazard ratio and P value, rather than relying only on the P value as most other analysts do, is to allow greater possibility of smaller groups (rarer trisomies) being entered into the model. The stepwise Cox model, which relies strictly on P values, will be much more dependent on the mix of trisomies (how close to 50% have the trisomy?) than the method that combines both hazard ratio and P value. This is especially important if outstanding prognosis subgroups are sought. The hazard ratio has the same interpretation irrespective of the mix of trisomies. Nonetheless, both methods will have a difficult time entering very rare but outstandingly prognostic trisomies in their respective models.
The verification process substantially reduces the chances of spurious findings, but also reduces the data available for modelling by 50%. It should only be used if patient numbers permit. If all patients are used for modelling, there is a higher probability of detecting truly significant trisomies, as well as a higher probability of falsely detecting truly nonprognostic trisomies as prognostic.
Stepwise procedures are good exploratory tools for finding a set of independent prognostic indicators. Generally, after adjusting for the variables in the model, no other variables will be significantly prognostic. However, there may be other sets of explanatory variables that are as predictive or even more predictive than those derived in the stepwise process. In other words, no uniqueness can be assumed concerning the results of a stepwise procedure. For example, a small difference in P values could make a major difference as to which variable enters first into the stepwise Cox model. The final model resulting from these alternate first steps could be very different, although both might explain differences in outcome very well. EFS curves were constructed by the method of Kaplan and Meier,26 with standard errors as described by Pet0 et al,27 for the final risk groupings of the test and verification data sets, respectively. Stratified logrank tests were used to analyze the independent prognostic importance of (1) trisomy and risk groups defined by Trueworthy et all3 and (2) trisomy and treatment.
RESULTS
The first step of the recursive partitioning analysis is shown in Tables 3 and 4 . With use of the test data set, it can be seen that trisomies of chromosomes 4,5,6,10,14,17,18, 21, and X are univariately associated with a superior EFS (P < .01). Of these abnormalities, trisomy 10 had the smallest estimated hazard ratio (0.16) and, therefore, was selected as the primary partition. The full details of recursive partitioning appear in Tables 5 and 6 . Among trisomy 10 patients, trisomy 4 was the strongest prognostic variable, whereas within the group of patients lacking trisomy 10, no specific trisomy met the P < .01 criterion.
Two patient subgroups (1) without trisomy 10 or (2) with trisomy 10 but without trisomy 4 could be amalgamated, but no further partition based on trisomy could be made.
The recursive partition resulted in two subgroups: one with trisomy of both chromosomes 4 and 10, and one with trisomy of, at most, one of these two chromosomes. This subgrouping was prognostically significant in the verification data set (P < .001). In fact, simultaneous trisomy of chromosomes 4 and 10 was prognostically significant in the verification data set (P < .05) for each treatment regimen except A, to which patient entry was restricted to the group at lower risk of treatment failure. The overall P value in the verification set, stratified for treatment, was < .001, indicating that the prognostic significance of these trisomy groups cannot be attributed to therapeutic differences. Trueworthy et all3 established a three-level risk grouping for B-progenitor cell ALL, as follows: (1) DNA index greater than 1.16; ( 2 ) DNA index I 1.16, age I 11.0 years, and leukocyte count less than 50 x lo9& (3) DNA index -< 1.16, age greater than 11.0 years, and/or leukocyte count 2 50 x 109/L. After stratifying for the above risk grouping, none of the variables studied by Trueworthy et all3 was prognostically significant. Table 7 presents the analysis of the prognostic importance of trisomy 4 and 10 within these risk groups. Table 8 Step 4: Partition Attempt ~ No trisomy met criterion.
Final grouping (P < ,001 in verification data set A v 6). For Comparison of EFS for group 1 v group 2 (test data): P < ,001. Comparison of EFS for group 1 v group 2 (verification data): P < .001.
trisomy of both chromosomes 4 and 10 is not associated with a superior outcome (4-year EFS of 70.4% 2 11.5% v an overall 4-year EFS of 72.4% 2 2.6% among all 1,896 eligible patients).
To describe the patient subgroups, clinical information is as follows. Of the 783 patients with at most one trisomy of chromosomes 4 and 10, 50% had translocations, median chromosome count was 46, median leukocyte count was 11.9 x 109/L, and median age was 4 years. Of the 238 patients with trisomy of both chromosomes 4 and 10, 18% had translocations, median chromosome count was 56, median leukocyte count was 6.0 x 109/L, and median age was 4 years. By these clinical features, one would expect the group with trisomy of both 4 and 10 to have a better prognosis than those with at most one of these trisomies. However, these clinical features alone cannot explain the extent of the difference in EFS.
DISCUSSION
The most important finding of this study is that information obtained from the leukemia cell karyotype permits accurate identification of a subgroup of children or adolescents with B-progenitor cell ALL who appear curable with antimetabolite-based chemotherapy. Prospective identification of this low-risk group should stimulate the development of risk-specific therapy in future studies, thus leading to an improved quality of life both during and after therapy, while preserving a high rate of cure.
That patients with trisomy of chromosomes 4 and 10 have a 4-year EFS of approximately 95% is remarkable. However, a current limitation to the use of trisomy as a prognostic factor is that the karyotype cannot be consistently determined in all newly diagnosed cases of ALL. The proportion of patients having an identifiable abnormal clone was just over one-half in this study (1,021 of 1,896, 54%), which relied on a central reference laboratory for karyotype determination. This result contrasts with the 90% detection rate reported by Williams et ala from a single institution. A selection bias may thus be present in our study, and results can be considered valid only for patients with identified clonal abnormalities. For example, patients with a clonal abnormality had a 4-year EFS of 66.9% (n = 1,021; SE = 3.9%) as compared with the remaining eligible patients' 4-year EFS of 78.8% (n = 875; SE = 3.2%; P = .018).
The biologic explanation for these prognostic associations is not entirely clear. The patient group with combined trisomy of chromosomes 4 and 10 appear to have more prognostically favorable clinical features. Even so, the favorable correlation with EFS of trisomy of chromosomes 4 and 10 cannot be attributed entirely to a higher frequency of lower-risk clinical features, because the presence of such trisomy retained prognostic importance within the groups defined by DNA index, age, and white blood cell count (WBC), the complete set of independently prognostic indicators found by Trueworthy et all3 ( Table 7) .
The strong association of hyperdiploidy of leukemic cell chromosomes with favorable treatment outcome was originally reported by Secker-Walker et all0 and since confirmed by other^.^,^,^^ Patients whose leukemic cell karyotypes contain greater than 51 or 52 chromosomes have been reported to have a more favorable prognosis than those with lower ploidy,' although a precise causal explanation for this finding is lacking. Further, the DNA index deter- mined by flow cytometry (ratio of leukemia cell DNA content of Go/GI cells to that of normal diploid cells), which can be done cheaply, rapidly, and with near uniform success, provides a good estimate of the chromosome number per cell ( 2 2 whole chromosomes) and has also been strongly associated with prognosis. The rate of successful DNA flow cytometry in the present study (84% of cases with a detectable clonal abnormality) is lower than might be expected because a DNA index was determined only if marrow remained after the mandatory immunophenotyping and cytogenetic studies. When a sample was submitted for DNA analysis, the success rate was 99%. Use of DNA ploidy alone has enabled investigators to identify a subgroup of patients with a 4-year EFS of 75% to 9O%.l2J3 We previously reported that hyperdiploidy greater than 51 was associated with an improved treatment outcome and that trisomy of several autosomes, including 6, 12, and 21, was associated with a better EFS within the greater than 51 chromosome group. We were unable to identify a cohort of patients whose prognosis was as favorable as that for the trisomy 4 and 10 subgroup in the present study.9 This failure can be explained partly by the lower success rate and the poorer quality of cytogenetic studies in the first investigation, in which a central reference laboratory was not available, and by the generally less effective treatment regimens that were used and were associated with significantly higher rates of bone marrow relapse. Moreover, there were no efforts made to obtain DNA indices. In a more recent analysis, we showed the value of DNA index, leukocyte count, and age as predictors of treatment outcome in patients with B-progenitor ALL treated on the POG ALinC 14 study reported here.13 We have extended our previous observations by showing the independent prognostic importance of trisomy of chromosomes 4 and 10 among hyperdiploid cases in general, providing further insight as to which trisomic chromosomes are most strongly associated with the favorable prognosis consistently reported for hyperdiploid ALL. These results suggest that increased copy number of genes located on chromosomes 4 and 10 may render leukemic lymphoblasts more sensitive to one or more of the chemotherapeutic drugs used in this trial, perhaps by altering intracellular drug metabolism, as had been suggested by Whitehead et Surprisingly, patients with a favorable DNA index, but lacking trisomy of chromosomes 4 and 10, fared suboptimally on POG regimens (4-year EFS of 70%), in contrast to patients with an unfavorable DNA index but with trisomy of chromosomes 4 and 10 (all 19 remain in complete remission). This information suggests that, provided clonal abnormalities are identified, trisomy of these two autosomes should be given more prognostic weight than a favorable DNA index when one attempts to assign children to protocols of minimal therapy. Optimal therapy for "lower risk" children with ALL defined in this way remains to be determined by prospective randomized trials building upon these findings.
Our recursive partitioning method with verification selects patient subgroups on the basis of the hazard ratio for treatment failure, not strictly because of a small P value.21 This makes it more sensitive to finding subgroups with an excellent prognosis. Methods purely based on P values tend to be much more dependent on the relative sizes of the subgroups.
The results described here would be more generally applicable if cellular genetic defects could be identified in cases without fully banded karyotypes. Recently, fluorescence in situ hybridization (FISH) analysis has been introduced and is being widely applied in the study of genetic abnormalities in malignancies. It can detect specific chromosomes directly on metaphase or interphase spreads of human chromosomes using chromosome-specific probes, and has been used to detect trisomies, particularly trisomy 9 in acute myeloblastic le~kemia.3~ Further application of this technique should make it possible to test the predictions of a recursive partitioning model on a large group of children with ALL.
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